Sandoz receives approval by European Commission for Hyrimoz® (adalimumab) high-concentration formulation Biosimilar Hyrimoz® (adalimumab) citrate-free high-concentration formulation (HCF) is now approved in the EU for use in all indications of reference medicine Humira®*HCF formulation adalimumab offers...

Sandoz Biologics License Application for proposed biosimilar denosumab accepted by US FDA Submission supported by comprehensive analytical and clinical data package Denosumab indicated for treating variety of conditions including osteoporosis in postmenopausal women1,2 Sandoz...

IncludeHealth Secures Licensing Agreement from Cincinnati Children’s Hospital Medical Center Cincinnati, OHIO, Dec. 18, 2019 (GLOBE NEWSWIRE) -- IncludeHealth, an internationally recognized provider of inclusive digital health and performance technologies, and Cincinnati Children’s Hospital...

eWellness Announces Renewed Focus on the $4 Billion North American Musculoskeletal Treatment Market Culver City, CA, July 03, 2019 (GLOBE NEWSWIRE) -- eWellness Healthcare Corporation – (OTCQB: EWLL) – a provider of the state of the art PHZIO platform for the physical therapy (“PT”) and telehealth...